| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Myristoyl coenzyme A lithium targets N-myristoyltransferase (NMT), the enzyme that catalyzes the transfer of myristate from myristoyl-CoA to the N-terminal glycine of target proteins. Protein myristoylation is a lipid modification that is essential for the function of many proteins, including those involved in viral replication and cancer cell signaling. NMT is a validated target for antiviral and anticancer drug discovery. |
|---|---|
| ln Vitro |
In vitro, Myristoyl coenzyme A lithium serves as a substrate for NMT in enzymatic assays to measure NMT activity. The compound is used to study the kinetics of myristoylation reactions and to screen for NMT inhibitors. By providing a labeled or unlabeled myristoyl donor, the compound enables the characterization of NMT substrate specificity and the identification of myristoylated proteins in cell lysates.
|
| ln Vivo |
In vivo, Myristoyl coenzyme A lithium has potential applications in studying the role of myristoylation in viral replication and cancer. By modulating the myristoylation of viral proteins or oncoproteins, the compound could be used to investigate the therapeutic potential of targeting NMT. Detailed in vivo studies would require the use of cell-permeable analogs or inhibitors that can modulate NMT activity in living organisms.
|
| Enzyme Assay |
Non-cellular enzyme assays using Myristoyl coenzyme A lithium are performed by incubating the compound with purified NMT enzyme and a peptide substrate containing an N-terminal glycine. The transfer of myristate to the peptide is monitored by detecting the myristoylated product using methods such as HPLC, mass spectrometry, or radiometric detection if labeled myristate is used. These assays are used to determine enzyme kinetics and to screen for NMT inhibitors.
|
| Cell Assay |
In vitro cellular experiments with Myristoyl coenzyme A lithium are challenging due to the compound's inability to cross cell membranes. However, cell lysates can be prepared and used to study NMT activity in the presence of the compound. Alternatively, cell-permeable NMT inhibitors can be used to study the effects of modulating myristoylation in cells. The compound can also be used in in vitro myristoylation reactions with purified proteins or cell lysates to identify myristoylated proteins.
|
| Animal Protocol |
In vivo animal experiments with Myristoyl coenzyme A lithium are not typically performed due to the compound's poor cell permeability and instability in biological fluids. However, the compound can be used in ex vivo assays with tissue homogenates. For in vivo studies of myristoylation, researchers typically use cell-permeable NMT inhibitors or genetic approaches to modulate NMT activity. The compound serves as a valuable tool for biochemical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not relevant for Myristoyl coenzyme A lithium as it is a substrate used in biochemical assays and not a therapeutic compound. The molecular formula is C35H62N7O17P3S·xLi+ with a molecular weight of approximately 977.89 (or 1001.62 for the tetralithium salt). The CAS number is 187100-75-0. Purity is typically ≥80% by HPLC. The compound should be stored according to the manufacturer's recommendations.
|
| Toxicity/Toxicokinetics |
Toxicity data for Myristoyl coenzyme A lithium are not typically characterized as the compound is a research reagent used in biochemical assays, not a therapeutic agent. Standard laboratory safety precautions should be followed when handling the compound. The lithium salt form may require special handling considerations. Researchers should consult the safety data sheet for specific handling and disposal guidelines.
|
| References | |
| Additional Infomation |
Myristoyl coenzyme A lithium is a lithium-labeled myristoylated coenzyme A. It serves as a substrate for N-myristoyltransferase (NMT). Myristoylation is an essential process in viruses and is controlled by NMT. The compound has potential applications in studying anticancer and antiviral mechanisms. All products are for research use only and not for human therapeutic applications.
|
| Molecular Formula |
C35H62N7O17P3S.XLI
|
|---|---|
| Exact Mass |
1001.346
|
| CAS # |
187100-75-0
|
| PubChem CID |
118855984
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
31
|
| Heavy Atom Count |
67
|
| Complexity |
1560
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
[Li+].[Li+].[Li+].[Li+].CCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)([O-])OP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)([O-])[O-])O
|
| InChi Key |
DMIGQCYHWKIMOK-RUVUOEETSA-J
|
| InChi Code |
InChI=1S/C35H62N7O17P3S.4Li/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42;;;;/h22-24,28-30,34,45-46H,4-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50);;;;/q;4*+1/p-4/t24-,28-,29-,30+,34-;;;;/m1..../s1
|
| Chemical Name |
tetralithium;[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[[[(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-tetradecanoylsulfanylethylamino)propyl]amino]butoxy]-oxidophosphoryl]oxy-oxidophosphoryl]oxymethyl]oxolan-3-yl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
